volume 28, issue 3, P313-319 2007
DOI: 10.2500/aap.2007.28.3003
View full text
|
Sign up to set email alerts
|
Share

Abstract: Anti-IgE therapy with omalizumab, a recombinant humanized monoclonal antibody, has anti-inflammatory effects in allergic asthma and rhinitis. Although omalizumab has been exceptionally safe, reactions after its administration have been reported. The goal of this study was to assess two patients who experienced apparent anaphylaxis after omalizumab administration. Two cases of apparent anaphylaxis after omalizumab administration are reported with diagnostic evaluation using skin testing and unique IgE and IgG a…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

1
50
0
1

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals